| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/16/2013 | US8420657 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors |
| 04/16/2013 | US8420630 Pyrimidine derivatives |
| 04/16/2013 | US8420591 MUC1 and galectin-3 |
| 04/16/2013 | US8420590 Genes and proteins that home to developing microvessels |
| 04/16/2013 | US8420396 For delivering DNA/RNA into cells |
| 04/16/2013 | US8420350 Glycosylation-deficient hepatocyte growth factor |
| 04/16/2013 | US8420340 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 04/16/2013 | US8420130 Pharmaceutical formulation of a didemnin compound |
| 04/16/2013 | US8420100 Tumor suppressor activating polypeptides and uses thereof |
| 04/16/2013 | CA2577938C Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| 04/16/2013 | CA2576531C 1,5-diphenylpyrazoles |
| 04/16/2013 | CA2574564C Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| 04/16/2013 | CA2559128C Kinase inhibitors |
| 04/16/2013 | CA2555694C Anti-epcam immunoglobulins |
| 04/16/2013 | CA2555248C Use of 2,5 dihydroxybenzenesulfonic acid, in the manufacturing of medicines, applicable to the treatment of angiodependent diseases |
| 04/16/2013 | CA2553887C Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 04/16/2013 | CA2486157C Opioid and opioid-like compounds and uses thereof |
| 04/16/2013 | CA2478169C Human antibodies specific to kdr and uses thereof |
| 04/16/2013 | CA2361246C Identification of specific differentially expressed antigens |
| 04/16/2013 | CA2271783C Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 04/14/2013 | CA2788253A1 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| 04/11/2013 | WO2013052943A2 Small molecule inhibitors of mcl-1 and uses thereof |
| 04/11/2013 | WO2013052888A1 Hsf 1 as a marker in tumor prognosis and treatment |
| 04/11/2013 | WO2013052772A2 Anti-human sema4a antibodies useful to treat disease |
| 04/11/2013 | WO2013052727A1 Methods of treatment using modulators of sirt2 |
| 04/11/2013 | WO2013052699A2 Novel quinoxaline inhibitors of pi3k |
| 04/11/2013 | WO2013052465A1 [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer |
| 04/11/2013 | WO2013052157A1 Crystalline forms of afatinib di-maleate |
| 04/11/2013 | WO2013052006A1 Parp-1 inhibitors |
| 04/11/2013 | WO2013051891A1 Anti c-met antibody and uses thereof |
| 04/11/2013 | WO2013051878A2 Antibody specifically binding to epitope in sema domain of c-met |
| 04/11/2013 | WO2013051778A1 Conjugate having tumor selectivity for targeted treatment |
| 04/11/2013 | WO2013051767A1 Novel use of angiogenin |
| 04/11/2013 | WO2013051672A1 Medicinal agent comprising thiazolidine derivative or salt thereof as active ingredient |
| 04/11/2013 | WO2013051632A1 Nitrogen-containing fused heterocyclic compound |
| 04/11/2013 | WO2013051459A1 Promoter capable of promoting inhibition of expression of mrna by rna interference, and use thereof |
| 04/11/2013 | WO2013051389A1 Medicinal agent responsive to metal salen complex compound, and system for controlling in vivo behavior of metal salen complex compound |
| 04/11/2013 | WO2013051363A1 Magnetic composition, and method for producing same |
| 04/11/2013 | WO2013051001A1 Combination therapy with erbb ligands binding molecules |
| 04/11/2013 | WO2013050725A1 Ige anti -hmw-maa antibody |
| 04/11/2013 | WO2013050644A1 Enantiomers of 2-hydroxy derivatives of fatty acids |
| 04/11/2013 | WO2013050476A1 New apoptosis inducing compounds |
| 04/11/2013 | WO2013050448A1 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| 04/11/2013 | WO2013050446A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| 04/11/2013 | WO2013050438A1 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. |
| 04/11/2013 | WO2013050379A1 Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
| 04/11/2013 | WO2013025939A9 Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| 04/11/2013 | WO2012175798A3 Combination therapy |
| 04/11/2013 | WO2012170976A3 Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| 04/11/2013 | WO2012170776A3 Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy |
| 04/11/2013 | WO2012170720A3 Methods and compositions for treating brain cancer |
| 04/11/2013 | WO2012166987A3 Liphagal enantiomers and their derivatives and precursors, and enantioselective methods of making the same |
| 04/11/2013 | WO2012158843A3 Kinase inhibitors |
| 04/11/2013 | WO2012153193A3 Protein-active agent conjugates and method for preparing the same |
| 04/11/2013 | WO2012129145A8 Nsclc combination therapy |
| 04/11/2013 | WO2012104788A3 Anti-angiogenic compounds, pharmaceutical compositions containing same, and use thereof |
| 04/11/2013 | WO2012100957A8 Inhibitors of branched-chain-aminotransferase-1 (bcat1) for the treatment of brain tumors |
| 04/11/2013 | WO2001027079A3 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 04/11/2013 | US20130091591 Artery- and vein-specific proteins and uses therefor |
| 04/11/2013 | US20130090362 Guanidinyl-substituted polyamides useful for treating human papilloma virus |
| 04/11/2013 | US20130090312 Methods of use related to xerostomia |
| 04/11/2013 | US20130090297 Nutritional compositions |
| 04/11/2013 | US20130089927 Hematopoietic Cell E-Selectin/L-Selectin Ligand Polypeptides and Methods of Use Thereof |
| 04/11/2013 | US20130089627 Method for treating a cancer caused by cancer stem cells |
| 04/11/2013 | US20130089615 Compositions of Jasmonate Compounds and Methods of Use |
| 04/11/2013 | US20130089569 Recombinant mva capable of expressing structural hcv antigens |
| 04/11/2013 | US20130089561 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 04/11/2013 | US20130089557 Antibody specifically binding to epitope in sema domain of c-met |
| 04/11/2013 | US20130089556 Anti c-met humanized antibody and uses thereof |
| 04/11/2013 | US20130089542 Anti c-met antibody and uses thereof |
| 04/11/2013 | US20130089534 Methods for assisting anti-cancer drugs |
| 04/11/2013 | DE102004041612B4 Extraktion von Carotinen, Vitamin E und anderen in geringer Menge vorliegenden Bestandteilen aus natürlichen Fetten und Ölen mit überkritischen Fluiden Extraction of carotenes, vitamin E and other ingredients present in small amounts from natural fats and oils with supercritical fluids |
| 04/11/2013 | CA2851244A1 Anti-human sema4a antibodies useful to treat disease |
| 04/11/2013 | CA2851220A1 Antibody specifically binding to epitope in sema domain of c-met |
| 04/11/2013 | CA2851135A1 Anti c-met antibody and uses thereof |
| 04/11/2013 | CA2851037A1 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases |
| 04/11/2013 | CA2850944A1 Human notch1 decoys |
| 04/11/2013 | CA2850779A1 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
| 04/11/2013 | CA2850763A1 Novel quinoxaline inhibitors of pi3k |
| 04/11/2013 | CA2849421A1 Malignant and non-malignant disease treatment with ras antagonists |
| 04/11/2013 | CA2849335A1 Methods and systems for identifying and treating anti-progestin sensitive tumors |
| 04/11/2013 | CA2848842A1 Ige anti -hmw-maa antibody |
| 04/10/2013 | EP2578682A1 Antibody and use thereof |
| 04/10/2013 | EP2578678A1 Method for producing tumor cell |
| 04/10/2013 | EP2578643A1 Fluorescent dye material and use thereof |
| 04/10/2013 | EP2578587A1 Pyrazole derivatives |
| 04/10/2013 | EP2578585A1 Purinone derivative |
| 04/10/2013 | EP2578584A1 Arylamino purine derivatives, preparation method and pharmaceutical use thereof |
| 04/10/2013 | EP2578583A1 Fused heterocyclic derivatives and methods of use |
| 04/10/2013 | EP2578580A1 G, I and K crystal forms of imatinib mesylate |
| 04/10/2013 | EP2578574A1 Optically active dibenzylamine derivative, and manufacturing method for same |
| 04/10/2013 | EP2578573A1 Fused imidazole derivative |
| 04/10/2013 | EP2578233A1 Therapeutic agent for pancreatic cancer |
| 04/10/2013 | EP2578231A1 Antitumor t cell response enhancer |
| 04/10/2013 | EP2578227A2 Cancer therapy method |
| 04/10/2013 | EP2578225A1 Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer |
| 04/10/2013 | EP2578186A2 Drug-delivery endovascular stent and method for treating restenosis |
| 04/10/2013 | EP2576638A2 Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| 04/10/2013 | EP2576622A1 ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
| 04/10/2013 | EP2576614A2 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis |